Table 2.
Evolution of DMARD treatment and disease during the first year for ESPOIR patients with early rheumatoid arthritis (RA).
| First DMARD | Treatment at 1 year | |||||
|---|---|---|---|---|---|---|
| Type | N | Delay between RA onset and DMARD start (weeks)a | N | DAS28(ESR)-4v at baseline | DAS28(ESR)-4v at 1 year | |
| Methotrexateb | 335 | 26.7 ± 11.6 (24.3) | Methotrexate | 302 | 5.3 ± 1.3 (5.2) | 3.2 ± 2.7 (3.0) |
| 35 ± 15.3 (39.4) | Other synthetic DMARD(s)c | 19 | 5.3 ± 1.4 (5.3) | 4.1 ± 1.5 (4.1) | ||
| 30.5 ± 0.7 (21.6) | Biologic agentd | 11 | 5.7 ± 0.4 (5.5) | 3.9 ± 0.9 (4.2) | ||
| Leflunomide | 35 | 48.9 ± 11.6 (46.9) | Methotrexate | 9 | 5.8 ± 1.3 (5.6) | 4.0 ± 2.7 (2.9) |
| 22.5 ± 15.3 (20.7) | Other synthetic DMARD(s) | 24 | 5.4 ± 1.4 (5.5) | 3.3 ± 1.5 (3.0) | ||
| 37.8 ± 0.7 (37.8) | Biologic agentd | 2 | 5.9 ± 0.4 (5.9) | 4.2 ± 0.9 (4.2) | ||
Data are mean ± SD (median). aDelay between RA onset and DMARD start (weeks) (P = 0.479): Methotrexate: 27.2 ± 15.1 (24.7); Leflunomide: 30.1 ± 18.1 (24.6); bat one year: one patient did not receive any DMARDs and data for two patients were not available; cleflunomide or salazopyrine; dadalinumab, etanercept, infliximab or anakinra. DAS28(ESR)-4v, Disease Activity Score in 28 joints-4 variables, using erythrocyte sedimentation rate; DMARD, disease-modifying anti-rheumatic drugs; N, number.